The board claim starts in a lab that did not exist yet
Claim on the pink board: finasteride began as a molecule hunt. Label the origin instead as a clinic note that already knew which enzyme to block.
Most origin stories for oral drugs start with a screening deck and a lucky hit. Finasteride does not. Before Merck had a 4-azasteroid in a flask, field endocrinologists already knew what happens when type 2 5-alpha-reductase never works. Infants in isolated Dominican settlements were often raised as girls. At puberty a delayed male pattern arrived - voice, muscle, genital change villagers nicknamed guevedoces, roughly 'penis at twelve.' Folklore until someone mapped the biochemistry.
Julianne Imperato-McGinley published that map in the mid-1970s. Testosterone was present. Conversion to dihydrotestosterone was not. One missing enzyme explained the whole picture, including two adult findings that later became product labels: small prostates and almost no male-pattern balding. That is a target, not a rumor. Strike the idea that chemists invented the question. They inherited it.
What Imperato-McGinley put on paper in 1974
The 1974 papers were not travel writing. They were a natural experiment with a clean split: circulating testosterone stayed in range, DHT did not, and the tissues that need DHT stayed small. External genitalia and the prostate depend on that conversion before birth and in early infancy. Without it, newborns look female or ambiguous. Puberty later floods the system with testosterone, which is enough to push much of male maturation through - late, and never quite complete. Villagers had already named the delay. The papers named the enzyme. That order still governs the file.
James Hamilton had already shown, in 1947, that men without testicular androgens do not go bald in the usual pattern. Imperato-McGinley added the missing enzyme name. Baldness and prostate growth were not 'male hormone' in the vague sense. They were DHT-amplified jobs. Once that sentence exists, a drug company can ask a practical question: can an adult take a reversible version of the gap without undoing anatomy that already finished decades earlier?
The jobs DHT keeps that testosterone does not
File this split before you read any later milligram: testosterone carries most of what people mean by male function. DHT is a local amplifier in a short list of tissues.
DHT drives external genital formation and prostate budding in fetal life. It also miniaturises genetically vulnerable scalp follicles over years. Acne and a receding hairline were rare in the enzyme-deficient men, even with normal testosterone. Muscle, sperm production, and much of adult drive still ran on the parent hormone. That is why a selective type 2 blocker can shrink a gland and slow a hairline without flattening every androgen effect in the body.
Selective is not the same as silent. Type 2 5-alpha-reductase sits in prostate, genital skin, and the outer root sheath of follicles. Type 1 lives more in sebaceous skin. Finasteride hits type 2 hard and type 1 weakly. Dutasteride later blocked both. The history file only needs this: Merck copied the isoform the children lacked. Every later argument about sexual signals, PSA, and hair density still hangs on that one lever. How the lever is used at 1 mg versus 5 mg is a different article - the 1 mg versus 5 mg evidence file.
Merck set out to copy a missing enzyme
Roy Vagelos's group at Merck treated the Dominican phenotype as a design brief. Induce the enzyme gap in a healthy adult. Keep it reversible. Do not touch fetal development that already finished. Chemists landed on finasteride, a synthetic 4-azasteroid that competitively inhibits type 2 5-alpha-reductase and does not bind the androgen receptor. It is not an anti-androgen in the receptor sense. It is a conversion brake.
Pharmacology matched the field note with unusual cleanliness. Circulating DHT falls about 65 percent within 24 hours of a 1 mg tablet. Testosterone stays near baseline or rises slightly as the conversion stall backs up the parent hormone. Plasma half-life is short - about 5 to 6 hours in men under 60, nearer 8 hours after 70 - yet enzyme blockade outlasts the blood level, which is why once-daily dosing works. Bioavailability of the 1 mg tablet averages about 65 percent and food does not matter. Those numbers sit on the Propecia 1 mg fact line. The history point is simpler: the molecule was built to impersonate a genetic state, not to invent a new one.
The 5 mg prostate tablet had to ship first
Strike the hair-first myth. The first approved job was an enlarged gland, because that is where the natural experiment pointed with the hardest clinical need.
An aging prostate keeps growing under DHT. The urethra narrows. Men get a weak stream, hesitancy, frequency, and night walking. Surgery was the main answer before 1992. If men born without the enzyme kept small glands, a pill that lowered DHT should shrink an overgrown one. Merck filed Proscar, finasteride 5 mg, and the FDA cleared it on 19 June 1992 for symptomatic benign prostatic hyperplasia - the first 5-alpha-reductase inhibitor on a US label.
Benefit was real and slow. Volume drops over months, not days. Later four-year work (PLESS) added the endpoints that change practice: fewer acute retention events and fewer operations. Those numbers belong in the evidence file, not here. What the history file keeps is sequence. Hair was a footnote inside a urology program until someone noticed that a much smaller daily dose still moved scalp counts.
How a 1 mg hair line grew out of a gland program
Male-pattern thinning is DHT acting on follicles that are genetically set to miniaturise. Cut the amplifier and you brake the shrink, sometimes enough to thicken a crown. Prostate trial men, and the original enzyme-deficient adults, had already hinted at that. Merck ran hair-specific studies in men aged 18 to 41 with early vertex or mid-scalp loss and found the scalp answered at 1 mg daily - one-fifth of the Proscar strength - because type 2 in the follicle saturates early.
Propecia, finasteride 1 mg, was approved on 22 December 1997 for male-pattern hair loss in men only. Same compound. Same enzyme. Different tissue, different milligrams, different name. It was the first oral agent with randomised photo and count evidence for slowing genetic balding. It is contraindicated in women who are or may become pregnant. It is not a cure. Stop the tablet and DHT returns, and the hair line walks back. Practical limits and the sexual-signal row sit in the 1 mg cost and honesty guide.
File the arc: one lever, two later labels
James Hamilton links testicular androgens to common male balding after studying men with testicular insufficiency.
Julianne Imperato-McGinley reports Dominican children with type 2 5-alpha-reductase deficiency, low DHT, small prostates, and no pattern baldness.
Merck, under Roy Vagelos, builds finasteride as a reversible type 2 copy of that enzyme gap.
FDA clears Proscar, finasteride 5 mg, for symptomatic BPH - first drug in the class.
FDA clears Propecia, finasteride 1 mg, for male-pattern hair loss in men only.
PCPT reports fewer overall prostate cancers on 5 mg, with a debated high-grade excess.
Zoom out and finasteride is one of the few widely used tablets whose label logic was read almost straight from human genetics. A field endocrinologist saw that children missing one enzyme reached adulthood with tiny prostates and intact hairlines. A company built a reversible copy. Both later indications - gland shrinkage and scalp hold - were visible in that first clinic note years before either bottle shipped. That is rare. Most first-in-class stories wander. This one did not.
The arc also sets the honesty bar. The drug does one thing: block type 2 5-alpha-reductase and lower DHT. Every benefit and every complaint flows from that lever. It is not a miracle hair reset and it is not a free lunch. Sexual-signal questions, the 2012 persistence add on the label, and the PSA half-cut all belong to that same biochemistry. Dispute the numbers if you want. Do not dispute the origin. The 5-alpha story is the file, not the marketing. Keep the dates: 1974 named the enzyme, 1992 bottled the gland, 1997 bottled the hair line.